Janssen Pharmaceuticals, Inc. v. Mylan Laboratories Ltd.

Track this case

Case Number:

23-2042

Court:

Appellate - Federal Circuit

Nature of Suit:

835 Patent - (ANDA) (Fed. Qst.)

Companies

Sectors & Industries:

  1. July 01, 2025

    Full Fed. Circ. Rejects Mylan Rehearing Bid In Patent Case

    The full Federal Circuit on Tuesday shot down Mylan's request for the court to reconsider a March ruling that the company's planned generic version of schizophrenia drug Invega Trinza would cause physicians to infringe a Janssen patent.

  2. March 28, 2025

    Fed. Circ. Upholds Janssen's Patent Case Win Over Mylan

    The Federal Circuit declined on Friday to undo a lower court ruling that kept Mylan Laboratories Ltd. from releasing a generic version of Janssen Pharmaceuticals Inc.'s schizophrenia drug Invega Trinza, rejecting Mylan's challenge to a finding that the generic drug would cause physicians to infringe a patent covering its dosing regimen.